![]() ![]() ![]() N2 - Molecular alterations involving the PI3K/AKT/mTOR pathway (including mutation, copy number, protein, or RNA) were examined across 11,219 human cancers representing 32 major types. receives research support from Abbvie, Adelson Medical Research Foundation, AstraZeneca, the Breast Cancer Research Foundation, Critical Outcomes Technology, Horizon Diagnostics, Illumina, Ionis, Karus Therapeutics, Komen Research Foundation, Nanostring, Pfizer, Takeda/Millennium Pharmaceuticals, and Tesaro. is a consultant with AstraZeneca, Clovis Oncology, Genentech, Medivation, Casdin Capital, and Vermillion. ![]() has licensed an HRD assay to Myriad Genetics and is an SAB member/consultant with AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Ionis, Medimmune, Nuevolution, Pfizer, Precision Medicine, Signalchem Lifesciences, Symphogen, Takeda/Millennium Pharmaceuticals, and Tarveda, and has stock options with Catena Pharmaceuticals, ImmunoMet, Spindle Top Ventures, and Tarveda. T1 - A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations Publisher Copyright: 2017 Elsevier Inc.", ![]() ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2023
Categories |